Abstract 549P
Background
Interstitial pneumonia (IP) or interstitial lung abnormalities (ILA) is a risk factor for drug-induced interstitial lung disease (D-ILD) in immunotherapy. We usually evaluate interstitial pneumonia by CT findings without histopathological findings. We aimed to evaluate whether histopathological findings of the background lung in surgical specimens is correlated with development of D-ILD by immunotherapy in patients with postoperative recurrence.
Methods
Patients who were treated with immunotherapy or immunochemotherapy for first-line treatment of non-small cell lung cancer for postoperative recurrence from April 2017 to February 2023 were included. We retrospectively compared between characteristics of patients with and without D-ILD, including CT findings and histopathological findings of the background lung in surgical specimens.
Results
Among 32 included patients, we evaluated 27 patients whose surgical specimens were available. The median age was 72 years old, and 20 patients (74.1%) were male. Twelve patients (44.4%) had ILA on CT, and five patients (18.5%) had IP with usual interstitial pneumonia (UIP) pattern (two patients with UIP, one patient with probable UIP, and two patients with indeterminate for UIP) on pathology. Five patients (18.5%) developed D-ILD, including two patients with CTCAE grade 1, two patients with grade 2, and one patient with grade 5. Patients with D-ILD were significantly more likely to have ILA on CT than those without D-ILD (5/5[100%] vs. 7/22[31.8%], p<0.01). Although there was no significant difference, two of the patients with D-ILD had UIP pattern on pathology as compared with three of those without D-ILD (2/5[40%] vs. 3/22[13.6%] p=0.22). Four patients had both ILA on CT and UIP pattern on pathology, and two (50%) of these cases developed D-ILD.
Conclusions
In addition to chest CT findings, histopathological findings of the background lung in surgical specimens may be useful as predictors of D-ILD in immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Tanaka: Financial Interests, Personal, Speaker, Consultant, Advisor: Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo; Financial Interests, Personal, Royalties: Bunkodo Co., Ltd., Gakken Inc. N. Katsurada: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K. T. Nagano: Financial Interests, Personal, Invited Speaker: AstraZeneca K.K. M. Yamamoto: Financial Interests, Personal, Speaker, Consultant, Advisor: Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., Daiichi Sankyo, Taiho Pharmaceutical Co., Ltd. M. Tachihara: Financial Interests, Personal, Invited Speaker: Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd, AstraZeneca K.K, MSD K.K., Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Pfizer Japan Inc., Daiichi Sankyo, Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Research Grant: AstraZeneca K.K., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract